File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Excellent outcome of acute lymphoblastic leukaemia with TCF3-PBX1 rearrangement in Hong Kong

TitleExcellent outcome of acute lymphoblastic leukaemia with TCF3-PBX1 rearrangement in Hong Kong
Authors
KeywordsAcute lymphoblastic leukaemia
EFS
Survival
t(1;19)
TCF3-PBX1
Issue Date2018
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
Pediatric Blood & Cancer, 2018, v. 65 n. 12, article no. e27346 How to Cite?
AbstractObjective: The aim of this study was to review clinical outcomes and prognosis of paediatric patients with acute lymphoblastic leukaemia (ALL) with TCF3-PBX1 rearrangement. Patients: All children in Hong Kong diagnosed with ALL with TCF3-PBX1 rearrangement over the past two decades were included. Methods: Six hundred and twenty-four newly diagnosed patients with ALL from four consecutive studies were enrolled from 1997 to 2016. Patients carrying TCF3-PBX1 rearrangement and patients at intermediate risk without the gene expression were compared for clinical characteristics, overall survival and event-free survival (EFS). Results: The TCF3-PBX1 rearrangement was detected in 30 of 624 patients (4.8%). Results were consistent across the consecutive clinical trials employed in the past two decades. Compared with 239 intermediate risk patients without TCF3-PBX1 rearrangement, the 5-year overall survival and EFS for patients with TCF3-PBX1 rearrangement was superior, with both at 100% (P = 0.12 and P = 0.029). Conclusion: This population-based study over the past 20 years demonstrated that patients with TCF3-PBX1 rearrangement had favourable EFS compared with other intermediate risk patients treated with a similar chemotherapy backbone.
Persistent Identifierhttp://hdl.handle.net/10722/264247
ISSN
2017 Impact Factor: 2.646
2015 SCImago Journal Rankings: 1.505
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLin, A-
dc.contributor.authorCheng, FWT-
dc.contributor.authorChiang, AKS-
dc.contributor.authorLuk, CW-
dc.contributor.authorLi, RCH-
dc.contributor.authorLing, ASC-
dc.contributor.authorCheuk, KLD-
dc.contributor.authorChang, KO-
dc.contributor.authorKu, D-
dc.contributor.authorLee, V-
dc.contributor.authorHa, SY-
dc.contributor.authorLi, CK-
dc.date.accessioned2018-10-22T07:51:53Z-
dc.date.available2018-10-22T07:51:53Z-
dc.date.issued2018-
dc.identifier.citationPediatric Blood & Cancer, 2018, v. 65 n. 12, article no. e27346-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/264247-
dc.description.abstractObjective: The aim of this study was to review clinical outcomes and prognosis of paediatric patients with acute lymphoblastic leukaemia (ALL) with TCF3-PBX1 rearrangement. Patients: All children in Hong Kong diagnosed with ALL with TCF3-PBX1 rearrangement over the past two decades were included. Methods: Six hundred and twenty-four newly diagnosed patients with ALL from four consecutive studies were enrolled from 1997 to 2016. Patients carrying TCF3-PBX1 rearrangement and patients at intermediate risk without the gene expression were compared for clinical characteristics, overall survival and event-free survival (EFS). Results: The TCF3-PBX1 rearrangement was detected in 30 of 624 patients (4.8%). Results were consistent across the consecutive clinical trials employed in the past two decades. Compared with 239 intermediate risk patients without TCF3-PBX1 rearrangement, the 5-year overall survival and EFS for patients with TCF3-PBX1 rearrangement was superior, with both at 100% (P = 0.12 and P = 0.029). Conclusion: This population-based study over the past 20 years demonstrated that patients with TCF3-PBX1 rearrangement had favourable EFS compared with other intermediate risk patients treated with a similar chemotherapy backbone.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Cancer-
dc.subjectAcute lymphoblastic leukaemia-
dc.subjectEFS-
dc.subjectSurvival-
dc.subjectt(1;19)-
dc.subjectTCF3-PBX1-
dc.titleExcellent outcome of acute lymphoblastic leukaemia with TCF3-PBX1 rearrangement in Hong Kong-
dc.typeArticle-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.emailCheuk, KLD: klcheuk@hkucc.hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pbc.27346-
dc.identifier.pmid30051646-
dc.identifier.scopuseid_2-s2.0-85051017322-
dc.identifier.hkuros294453-
dc.identifier.volume65-
dc.identifier.issue12-
dc.identifier.spagearticle no. e27346-
dc.identifier.epagearticle no. e27346-
dc.identifier.isiWOS:000447556600006-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats